HC Wainwright Reaffirms Buy Rating for Opus Genetics (NASDAQ:IRD)

HC Wainwright reiterated their buy rating on shares of Opus Genetics (NASDAQ:IRD) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Opus Genetics’ Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at $0.00 EPS.

Opus Genetics Trading Up 5.1 %

NASDAQ:IRD opened at $0.98 on Tuesday. Opus Genetics has a twelve month low of $0.81 and a twelve month high of $1.56. The stock has a market capitalization of $31.40 million, a P/E ratio of -0.90 and a beta of 0.28. The stock has a 50-day simple moving average of $1.07.

Opus Genetics (NASDAQ:IRD) last announced its earnings results on Monday, March 31st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93). The firm had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $11.10 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. As a group, analysts expect that Opus Genetics will post -1.22 earnings per share for the current year.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.